Europeanhhm

First German EVBA Procedure is Performed with New Heart Failure Therapy Approach

Wednesday, July 27, 2022

Vascular Dynamics, Inc. (VDI), a leading medical device company specializing in endovascular solutions for heart failure patients, recently showcased its groundbreaking endovascular baroreflex amplification (EVBA) procedure using the MobiusHD device at the CSI Frankfurt 2022 25th anniversary Congress.

During the conference, the first-ever EVBA procedure for heart failure treatment in Germany was performed by Dr. Horst Sievert, Director of the CardioVascular Center in Frankfurt, and was broadcast live to the audience. Dr. Sievert expressed his satisfaction with the procedure, noting that the placement of the MobiusHD device using established techniques was flawless. This particular case marked the enrollment of the 30th patient in the ongoing clinical trial titled "A Feasibility Study Exploring the Effect of the MobiusHD Device in Patients with Heart Failure."

The EVBA procedure involves precise implantation of the MobiusHD device at the targeted location along the carotid body where baroreceptors are situated. It is a relatively quick procedure, typically completed in less than 30 minutes. This approach offers a potential solution for heart failure patients who have not responded well to drug treatments.

The live case demonstrating the EVBA procedure has been selected by CSI Education as its "Podcase of the Month" and can be viewed online for educational purposes.

In addition to the live case, Dr. Kerstin Piayda from the CardioVascular Center in Frankfurt presented updated results from the ongoing clinical trial during the CSI Frankfurt meeting. The data showcased improvements in outcomes for patients who received EVBA treatment with the MobiusHD device. Follow-up assessments conducted at 3, 6, and 12 months revealed positive responses among almost all study patients, with 90% experiencing improved quality of life and 100% demonstrating enhancements in six-minute walk distance (6MWD) and NT-proBNP biomarker levels. These results were deemed clinically meaningful, and there was also a promising trend indicating reduced heart failure hospitalizations at 6 and 12 months post-treatment.

Ed Roschak, CEO of Vascular Dynamics, expressed optimism about the results obtained thus far in the feasibility study for heart failure patients. With a recent $20 million financing round, the company is expanding its efforts to multiple clinical centers worldwide and actively enrolling more patients to further validate the benefits of the MobiusHD device.

Vascular Dynamics, Inc. continues to make significant strides in the field

Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare CNO SummitHealthcare CMO Summit